论文部分内容阅读
目的:建立雌/孕激素受体(ER/PR)阴性和阳性乳腺癌的蛋白质表达谱,寻找ER/PR阴性和阳性乳腺癌中差异表达蛋白,为乳腺癌患者提供新的预后预测指标和治疗新靶点。方法:应用蛋白质组学i TRAQ技术建立ER/PR阳性和阴性乳腺癌的蛋白质差异表达谱,鉴定两组乳腺癌的差异表达蛋白,对部分差异表达蛋白进行生物信息学分析,包括蛋白功能注释和分类GO分析和KEGG通路分析。结果:应用i TRAQ蛋白质组学技术对乳腺癌组织进行了蛋白组学分析,鉴定出ER/PR阳性和阴性组间有差异表达的蛋白4999种,以ER/PR阳性:ER/PR阴性≥3为上调标准,确定ER/PR阳性组上调蛋白101种。以ER/PR阳性:ER/PR阴性≤0.5为下调标准,ER/PR阳性组下调蛋白122种。GO分析结果显示ER/PR受体阴性和阳性乳腺癌的差异表达蛋白的分子功能、生物过程、细胞定位较为复杂,并且在上调蛋白和下调蛋白上存在分布差异。KEGG通路分析发现部分差异表达蛋白涉及201条信号通路。结论:ER/PR阳性和阴性乳腺癌间存在差异表达蛋白,这些蛋白涉及复杂的分子功能、生物过程和信号通路。
OBJECTIVE: To establish the protein expression profile of estrogen / progesterone receptor (ER / PR) negative and positive breast cancer and to find differentially expressed proteins in ER / PR negative and positive breast cancers and to provide new predictive prognostic indicators and treatment for breast cancer patients New target Methods: Proteomic differential expression profiling of ER / PR positive and negative breast cancer was established by proteomics i TRAQ technique. The differentially expressed proteins of two groups of breast cancer were identified. Some of the differentially expressed proteins were analyzed by bioinformatics analysis including protein functional annotation and Classification GO analysis and KEGG pathway analysis. RESULTS: Four hundred and ninety-nine proteins with differentially expressed ER / PR positive and negative were identified by using i TRAQ proteomics to detect breast cancer. ER / PR positive: ER / PR negative ≥ 3 To up-regulate the standard, 101 ER / PR-positive proteins were identified. To ER / PR positive: ER / PR negative ≤ 0.5 for the down regulation, ER / PR-positive group down 122 proteins. The results of GO analysis showed that molecular function, biological process and cellular localization of differentially expressed proteins of ER / PR receptor negative and positive breast cancer were complex, and there were differences in the distribution of upregulated proteins and downregulated proteins. KEGG pathway analysis found that some of the differentially expressed proteins involved in 201 signaling pathways. CONCLUSION: There are differentially expressed proteins between ER / PR positive and negative breast cancers and these proteins involve complex molecular functions, biological processes and signaling pathways.